Interview with Ingo Raimon, General Manager, AbbVie Austria
You have had an extensive career at the company, since 1989. What does the company have to offer that has made you stay so long and dedicated? AbbVie is a…
Address: Vorgartenstraße 206b
A-1020 Wien
,Austria
Tel: +43 (0)1 610 30 – 0
The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.
Cardiovascular and metabolic disorders
Through our pharmaceutical research and development efforts, we are developing innovative solutions and medications that can help people around the world living with diabetes, obesity, thrombosis and other chronic and potentially life-threatening conditions.
Immunology
Building upon our long-standing commitment to immunology, we continue to deliver new options to combat complex conditions, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis. Our rich heritage of innovation in biological research and medicines has allowed us to expand to oral and inhaled medicines for immunologic and pulmonary diseases.
Infectious diseases and vaccines
With a goal to improve public health by fighting infectious diseases worldwide, we are dedicated to delivering treatments for people living with HIV/AIDS, hepatitis C, tuberculosis, and other infectious diseases. Recently, we entered the field of prevention with the acquisition of Crucell, a company that develops vaccines and antibodies. As a result, we have a number of marketed vaccines and have furthered our pipeline based on Crucell’s unique technologies.
Neuroscience
With a longstanding, continued commitment to neuroscience, our vision is to reduce the burden, disability and devastation caused by serious neuropsychiatric diseases and pain conditions and restore hope for patients. Our areas of focus include: Neurology, which includes Alzheimer’s disease; psychiatry, focused on mood disorders, such as bipolar disease and major depressive disorder, and schizophrenia; and pain, where we have particular interest in chronic pain states and neuropathic pain.
Oncology
Through groundbreaking research and innovative partnerships, we aim to transform cancer into a preventable, chronic or curable disease. Our goal is to deliver diagnostic and therapeutic options that prolong and improve patients’ lives. We are focused on key cancer types, including ovarian cancer, hematologic malignancies, prostate cancer and lung cancers. We are dedicated to helping realize the promise of winning the “war on cancer.”
You have had an extensive career at the company, since 1989. What does the company have to offer that has made you stay so long and dedicated? AbbVie is a…
Prior to joining Kedrion you worked for CSL Behring for a number of years. What opportunities did you see for yourself in moving from there to Kedrion? The biggest opportunity…
LISAvienna celebrated its tenth anniversary in September. Could you briefly describe the core activities and organizational structure that has developed over the last decade? Austria has historically been quite strong…
Prior to founding Vela, you worked in a number of different positions with various companies such as Baxter and Octapharma. What opportunities did you see in founding your own company?…
Previously you worked for a pharmaceutical company, before moving to head up Eucodis Bioscience. What was your main motivation for switching from the pharmaceutical to the industrial biotech industry? The…
Could you please provide an overview of your main scope of activities in Austria and the importance of healthcare and pharmaceuticals to Boston Consulting Group’s (BCG) business model and revenue?…
You have been the CEO of Herba Chemosan since 2002. What were the initial goals you set for yourself when you took up this position, and where do we find…
Can you give our readers a brief overview of Daiichi Sankyo in Austria as well as its market positioning and growth factors in 2012? Daiichi Sankyo Austria GmbH is the…
How does the Austrian affiliate fit within Quintiles’ global structure, and what is the scope of the company’s activities here? Quintiles Austria was established in 1996 and has grown from…
Could you give our readers a snapshot of the association and its role in the Austrian pharmaceutical context? FOPI is a small and specialized industry association that has a homogenous…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
2012 marks the twentieth anniversary of Polymun. Can you describe to our readers the origins of the company and how it compares to your expectations in 1992? Prior to founding…
See our Cookie Privacy Policy Here
